Cancer Genetics (CGIX) Misses Q4 EPS by 2c

Cancer Genetics (NASDAQ: CGIX) reported Q4 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $7 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Greenlane Holdings Inc. (GNLN) reported Q2 result
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c